Return to study ST002066 main page
MB Sample ID: SA194273
| Local Sample ID: | K_5 |
| Subject ID: | SU002148 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | C57Bl/6 GEMMs |
| Age Or Age Range: | Mutants: K: 90 days, KK: 60 days, KL and KKL: 40 days post Ad5-CMV-Cre |
| Gender: | Male and female |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR002160 |
| Treatment Summary: | Mice were genotyped using primers outlined in the Key Resources Table. Seven-to-eight-week old conditional mice were intranasally (i.n) infected with 20 ul of 1x1010 PFU/ml Ad5-CMV-Cre virus (University of Iowa Gene Transfer Core Facility) according to standard procedures62. For anti-PD1 survival study, 20 days following Ad5-CMV-Cre, KL and KKL mice were randomly assigned to anti-PD1 or isotype control antibody (200 g RMP1-14 or Rat IgG2a; BioXCell) treatment arms (n = 6/arm). Each cycle (every 20 days) consisted of intra-peritoneal injection (200 l into left and right flank) three times over 6 days (day 0, 3, 6). Mice were collected at ethical endpoint for Kaplan Meier survival analysis. For combination anti-PD1/CB-839 study, 20 days following Ad5-CMV-Cre, KL mice were randomly assigned to vehicle/isotype, vehicle/anti-PD1, CB-839/isotype or CB-839/anti-PD1 treatment arms (study 1: n = 6/arm; study 2: n = 4/arm). On day 20, mice received one cycle of anti-PD1 or isotype control (as above) and 200 mg/kg CB-839 (2 % w/v CB-839; BLDpharm, in vehicle) or vehicle (20 % Solutol HS15 / 20 % SB-β-CD (Captisol) / 50 mM phosphate buffer, pH 7.4) twice daily by oral gavage until collection on day 29, when mice were collected 12 hours following the final dose. At harvest, mice were sacrificed by cardiac bleed and the left lung lobe was weighed and processed for flow cytometry with spleens, while right lung lobes were inflated with 4 % paraformaldehyde and processed for histology. |
| Treatment Compound: | 200 ug RMP1-14 or Rat IgG2a; Combination treatments: vehicle/isotype, vehicle/anti-PD1, CB-839/isotype or CB-839/anti-PD1 treatment arms |
| Treatment Route: | by oral gavage |
| Treatment Dose: | multiple dose 200 ug. Combination treatments: 200 mg/kg CB-839 (2 % w/v CB-839; BLDpharm, in vehicle) or vehicle (20 % Solutol HS15 / 20 % SB-β-CD (Captisol) / 50 mM phosphate buffer, pH 7.4) twice daily by oral gavage until collection on day 29, |
